10-Q: Schrödinger Inc. Reports Q3 2024 Results: Revenue Declines Amidst Strategic Shift

Schrödinger Inc. experienced a revenue decrease in Q3 2024, primarily due to a decline in drug discovery revenue, while software revenue showed modest growth.

Summary

• Schrödinger Inc. reported a total revenue of $35.3 million for the third quarter of 2024, a 17% decrease compared to $42.6 million in the same period of 2023.
• Software products and services revenue increased by 10% to $31.9 million, while drug discovery revenue decreased by 75% to $3.4 million.
• The company's net loss for the quarter was $38.1 million, compared to a net loss of $62.0 million in Q3 2023.
• For the nine months ended September 30, 2024, total revenue was $119.2 million, a 16% decrease compared to $142.5 million in the same period of 2023.
• The net loss for the nine months ended September 30, 2024 was $146.9 million, compared to a net income of $71.4 million for the same period in 2023.
• The company's cash, cash equivalents, restricted cash, and marketable securities totaled $398.4 million as of September 30, 2024.
• The company sold 323,085 shares of common stock under its at-the-market offering program for net proceeds of $8.7 million during the nine months ended September 30, 2024.

Sentiment

Score: 5

Explanation: The document presents mixed results. While software revenue shows growth and the company has a strong cash position, the significant decline in drug discovery revenue and the overall net loss temper the positive aspects. The new collaboration with Novartis is a positive development, but the company still faces significant risks and uncertainties.

Positives

• Hosted software revenue increased by 61% in Q3 2024, indicating strong growth in the company's cloud-based offerings.
• The company's net loss improved in Q3 2024 compared to the same period in 2023.
• The company has a strong cash position of $398.4 million as of September 30, 2024.
• The new collaboration with Novartis Pharma AG provides significant potential for future revenue through milestones and royalties.

Negatives

• Total revenue decreased by 17% in Q3 2024, primarily due to a significant decline in drug discovery revenue.
• Drug discovery revenue decreased by 75% in Q3 2024, indicating a potential slowdown in collaboration activities.
• The company reported a net loss of $146.9 million for the nine months ended September 30, 2024.
• On-premise software revenue decreased by 11% in Q3 2024, indicating a potential shift in customer preferences towards hosted solutions.

Risks

• The company's future profitability depends on increasing software sales, drug discovery revenue, and successful development and commercialization of drug products.
• The company's quarterly and annual results may fluctuate significantly, which could adversely impact the value of its common stock.
• The company relies on third parties for clinical trials and manufacturing, which may not perform satisfactorily.
• The company may require additional capital to fund its operations, and may not be able to raise it on acceptable terms.
• The company faces intense competition in both the software and drug discovery markets.
• The company's reliance on third-party cloud providers exposes it to potential disruptions and security breaches.
• The company's drug discovery collaborations may not result in commercially viable products or significant revenue.

Future Outlook

The company expects to continue to invest in its proprietary drug discovery programs and computational platform, and anticipates reporting initial data from its Phase 1 clinical trials in 2025. The company also expects that its drug discovery revenue will fluctuate from period to period due to the inherently uncertain nature of the timing of milestone achievements and its dependence on the program decisions of its collaborators.

Management Comments

• The company is focused on advancing its proprietary drug discovery programs and expanding its computational platform.
• The company is leveraging its platform to predict toxicity associated with binding to off-target proteins.
• The company is seeking to advance its SOS1 program through a collaboration.

Industry Context

The announcement reflects a trend in the biopharmaceutical industry where companies are increasingly focusing on computational methods for drug discovery. The collaboration with Novartis Pharma AG highlights the growing interest in leveraging AI and computational platforms for drug development. The company's shift towards proprietary drug discovery programs also reflects a broader trend of companies seeking to control their own pipelines and maximize commercial opportunities.

Comparison to Industry Standards

• Schrödinger's software revenue growth of 10% in Q3 2024 is moderate compared to some pure-play software companies, but is solid for a company with a dual focus on software and drug discovery.
• The 75% decline in drug discovery revenue is significant and highlights the volatility and uncertainty inherent in drug development collaborations, which is common in the biopharmaceutical industry.
• The company's net loss of $38.1 million in Q3 2024 is an improvement compared to the same period in 2023, but still indicates that the company is in a growth phase and not yet profitable.
• The company's cash position of $398.4 million is strong compared to many other companies in the biotechnology sector, providing a buffer for future investments and operations.
• The collaboration with Novartis Pharma AG is a significant deal, with potential milestones of up to $2.272 billion, which is comparable to other major pharmaceutical collaborations in the industry.

Related Party Transactions

• The company paid consulting fees to a member of its board of directors.
• The company recognized revenue from services provided to a specified group of third-party organizations under a grant from the Bill & Melinda Gates Foundation.
• The company recognized drug discovery contribution revenue related to funds received under an agreement with the Bill & Melinda Gates Foundation.
• The company recognized software contribution revenue related to funds received under an agreement with the Bill & Melinda Gates Foundation.
• The company received contribution revenue in connection with its agreement with Gates Ventures, LLC.

Stakeholder Impact

• Shareholders may be concerned about the decline in drug discovery revenue and the overall net loss.
• Employees may be affected by the company's strategic shift and potential changes in priorities.
• Customers may benefit from the company's continued investment in its software platform.
• Collaborators may be impacted by the company's focus on proprietary drug discovery programs.
• Creditors may be reassured by the company's strong cash position.

Next Steps

• The company plans to continue investing in its proprietary drug discovery programs and computational platform.
• The company anticipates reporting initial data from its Phase 1 clinical trials in the first and second half of 2025.
• The company will continue to seek collaborations to advance its drug discovery programs.
• The company will continue to expand its software sales to existing customers and increase its customer base.

Key Dates

Keywords

Schrödinger, Software, Drug Discovery, Computational Platform, Pharmaceutical, Biotechnology, Clinical Trials, Revenue, Net Loss, Collaboration, Milestones, Licensing, R&D